Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

ACON Laboratories Announces Breakthrough 4-in-1 Flowflex® Plus RSV + Flu A/B + COVID Home Test

October 28, 2025 at 03:00 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Single-Swab Solution: New Over-the-Counter Test Simultaneously Detects and Differentiates RSV, Flu A/B, and COVID from the Comfort of Home

SAN DIEGO, CA, October 28, 2025 /24-7PressRelease/ -- ACON Laboratories, Inc., a leading global medical device manufacturer, announced today that its Flowflex® Plus RSV + Flu A/B + COVID Home Test has received 510(k) clearance from the U.S. Food & Drug Administration (FDA). The Flowflex Plus RSV + Flu A/B + COVID Home Test (K251749) is an over-the-counter (OTC) rapid antigen test that can be administered in the comfort and privacy of consumers' homes. This new test will be manufactured domestically in ACON's state-of-the-art facility in San Diego, CA.

The Flowflex Plus RSV + Flu A/B + COVID Home Test is a lateral flow immunoassay intended for the rapid, simultaneous qualitative detection and differentiation of respiratory syncytial virus (RSV), influenza A, influenza B (Flu A/B), and SARS-CoV-2 (COVID) protein antigens. This test is authorized for non-prescription home use with self-collected anterior nares nasal swab specimens. This is not only the first device of its kind with four analytes in one test (4-in-1), and the first RSV home test, but it is also the first respiratory home test to earn FDA clearance for children aged 6-23 months when administered by an adult using ACON's proprietary nasal swab guard.

In summary, this innovative product is:
- The first FDA-cleared 4-in-1 respiratory home test
- The first FDA-cleared RSV home test
- The first FDA-cleared respiratory infection home test for children aged 6-23 months

"We are excited to introduce this game-changing 4-in-1 home test. This product further demonstrates our commitment to enabling consumers to take charge of their own health. Symptoms of respiratory infections can be similar, so knowing which infection you have is important for making early treatment decisions, which can lead to better outcomes. We expect the Flowflex 4-in-1 home test will bring peace of mind to parents of young children as well as the elderly, the immune-compromised, and those of us who are in contact with at-risk populations," commented VP of Sales & Marketing, Michael Lynch.

Flowflex continues to be America's #1 home test brand¹, and the Flowflex Plus RSV + Flu A/B + COVID Home Test will be widely available at major retailers later this year. A list of authorized distributors and retail partners can be found at www.flowflexcovid.com.

¹ SOURCE: Circana Retail Sales Data (Units sold)

---
Press release service and press release distribution provided by https://www.24-7pressrelease.com

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article